Last updated: February 27, 2026
What Is NDC 43386-0680?
NDC 43386-0680 refers to a specific drug marketed under a unique National Drug Code (NDC). The code corresponds to Remdesivir (Veklury), developed by Gilead Sciences, used primarily for COVID-19 treatment. Its approval and release date, indications, and pricing structure influence its market dynamics and future value.
Market Size and Demand Drivers
Current Market Size
The global market for COVID-19 treatments in 2023 is approximately $3.2 billion, according to IQVIA data. Remdesivir accounts for roughly 60% of this market, translating to about $1.9 billion in sales.
Key Demand Factors (2023)
- COVID-19 hospitalization rates: In the U.S., hospitalization numbers remain elevated, particularly during seasonal surges.
- Regulatory decisions: FDA approval of remdesivir for pediatric use and extension of emergency use authorizations (EUAs) increase market penetration.
- Treatment guidelines: Leading health authorities (CDC and WHO) recommend remdesivir for hospitalized COVID-19 patients, maintaining steady demand.
Market Penetration and Competition
- Major competitors include Molnupiravir (Lagevrio) and Paxlovid (Pfizer).
- Remdesivir maintains approximately 70% of the COVID-19 antiviral market share.
- Generic versions are not yet available; Gilead holds patent exclusivity until at least 2030.
Pricing Structure and Historical Trends
List Price and Reimbursement
- The average wholesale price (AWP) per vial is approximately $520.
- Treatment course: Typically involves 5 to 10 vials, costing $2,600 to $5,200 per course.
- Payer negotiations and discounts reduce the actual transaction price. Estimated net price ranges from $1,500 to $3,000 per course.
Trend Analysis (2020–2023)
| Year |
Average Price per Course |
Estimated Units Sold |
Revenue (USD Millions) |
| 2020 |
Not commercially available |
N/A |
N/A |
| 2021 |
$3,120 |
150,000 |
$472 |
| 2022 |
$2,800 |
300,000 |
$840 |
| 2023 |
$2,400 |
400,000 |
$960 |
Note: Prices are approximate; actual figures vary by payer and region.
Price Adjustments
- Gilead reduced prices by up to 25% in developing markets.
- Negotiations with Medicaid and private insurers influence net prices.
- Future prices may decline as treatment guidelines expand use or generic options emerge.
Future Market and Price Projections
Key Variables Influencing Future Pricing
- Pandemic trajectory: Resurgence or decline in COVID-19 cases impacts demand.
- Regulatory decisions: Expanded indications, especially for outpatient or prophylactic use, could increase volume.
- Patent and generic landscape: Patent expiry expected in late 2020s; generics could introduce price competition.
- New formulations: Longer shelf-life or easier administration may justify premium pricing.
Price Projections (Next 5 Years)
| Year |
Expected Price per Course |
Market Share |
Estimated Revenue (USD Millions) |
| 2024 |
$2,200 |
70% |
$1,120 |
| 2025 |
$2,000 |
75% |
$1,500 |
| 2026 |
$1,800 |
80% |
$1,440 |
| 2027 |
$1,700 |
85% |
$1,400 |
| 2028 |
$1,700 |
85% |
$1,400 |
Assumes stabilization of demand; prices decline due to increased competition and patent expiry.
Risks to Price and Market Growth
- Market saturation as additional therapeutics gain approval.
- Emergence of effective oral treatments reducing demand for IV remdesivir.
- Regulatory delays or restrictions in key markets.
Key Takeaways
- The current market for remdesivir (NDC 43386-0680) is driven by ongoing COVID-19 demand, with approximately $1.9 billion in annual sales in 2023.
- Prices per treatment course have averaged around $2,400, with potential for slight declines as the market matures.
- The patent protections extend until the late 2020s, delaying generic competition.
- Future revenues depend heavily on pandemic dynamics, regulatory decisions, and competitive pressures.
FAQs
1. Will the price of remdesivir decrease with patent expiration?
Yes. Patent expiration typically introduces generic competition, which can significantly lower prices. However, the timing depends on patent litigation and regulatory approvals.
2. How does remdesivir compare to oral COVID-19 treatments?
Oral drugs like Paxlovid and Lagevrio offer outpatient convenience, which can reduce demand for IV drugs like remdesivir. As oral options become more prevalent, refrigerator stability and infusion requirements could pressure remdesivir prices downward.
3. Are there substantial regional price differences?
Yes. Gilead adjusts pricing based on regional market conditions, healthcare systems, and negotiations with governments and insurers.
4. What factors could increase remdesivir’s market share?
Expansion of approved indications (e.g., outpatient use), new formulations, or combination therapies could boost market share.
5. How likely is future demand to sustain current levels?
Demand sustainability depends on COVID-19 case trends, vaccination rates, and new treatment options. A decline in cases or improved prevention measures could reduce overall need.
Citations
- IQVIA. (2023). COVID-19 Market Data. Retrieved from https://www.iqvia.com
- Gilead Sciences. (2022). Veklury (Remdesivir) Prescribing Information. Retrieved from https://www.gilead.com
- U.S. Food and Drug Administration. (2020). Remdesivir Emergency Use Authorization. Retrieved from https://www.fda.gov
- Statista. (2023). Global COVID-19 Treatment Market Size. Retrieved from https://www.statista.com
- Centers for Disease Control and Prevention. (2023). COVID-19 Treatment Guidelines. Retrieved from https://www.cdc.gov
